#United States #New York #biotech #Series B #Accropeutics

Accropeutics Secures $12 Million in Series B Plus Financing

Accropeutics Inc., a clinical-stage biotechnology firm renowned for its innovative approach in developing therapeutics, recently announced the successful closure of a $12 million Series B Plus financing round. This funding was spearheaded by Shenzhen Capital Group (SCGC) and included participation from Morningside Ventures, along with new investors such as Leader Venture Investment (SZTI) and Hefei Sci-Tec Venture Capital (HFST).

This infusion of capital serves several purposes, primarily extending the company's operational runway into the latter half of 2026. Accropeutics intends to allocate the funds towards advancing clinical data for its flagship asset, AC-101, a selective RIPK2 inhibitor currently in a Phase Ib clinical trial targeting patients with Ulcerative Colitis (UC).

Advancing Clinical Trials

In addition to AC-101, Accropeutics has a robust pipeline of clinical-stage assets. The pipeline includes AC-201, another critical asset identified as a selective TYK2/JAK1 inhibitor that is in a Phase II trial for moderate to severe Psoriasis, as well as AC-003, a RIPK1 inhibitor involved in an ongoing Phase Ib trial for acute Graft-versus-Host Disease (aGvHD).

Dr. Xiaohu (Jason) Zhang, Co-founder and CEO of Accropeutics, conveyed his enthusiasm regarding the funding. He stated, "With this round of finance, we can continue to propel our lead programs forward and strengthen our identity as an innovative, clinical-stage biotech company. I appreciate the support from both our existing and new investors who share our vision to transform therapeutic landscapes for various immune-mediated diseases with potential best-in-class treatments."

Company Overview and Vision

Founded on the cutting edge of biotechnology, Accropeutics is committed to discovering and developing novel therapeutics aimed at addressing immune-mediated inflammatory diseases via targeted molecular mechanisms of regulated cell death. The company's portfolio boasts several innovative compounds at different developmental stages—from lead optimization to clinical testing.

Currently, AC-101 has successfully passed Phase I clinical trials in Australia and China, paving the way for its ongoing Phase Ib trials. Meanwhile, AC-201 has also completed its Phase I studies across the same regions and is now advancing to a Phase II trial focused on Psoriasis in China. Lastly, AC-003 has wrapped up its Phase I clinical trials in both China and the United States, additionally moving into a Phase Ib trial for aGvHD, which highlights the company's rapid progress and commitment to research.

Future Prospects

With 23 patents issued in major markets including China, Japan, Korea, the US, and the EU, Accropeutics maintains exclusive global rights to its assets. The additional financing not only strengthens the company’s financial stability but also empowers its innovation strategies and clinical developments focusing on immune-related disorders. Accropeutics is dedicated to translating scientific discoveries into meaningful therapies that improve patient outcomes while addressing a substantial unmet need in the healthcare industry.

As Accropeutics continues on this trajectory, the firm stands at a promising intersection of scientific advancement and therapeutic innovation, further solidifying its foothold in the fast-evolving biotech arena.

For more detailed information about their pipeline and ongoing projects, visit Accropeutics’ official site.